The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the PI, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities. These activities include preparation of this competing renewal, non-competing renewals including progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, and assurance that the labs supported by this Program are in full compliance with all institutional, state and federal regulations. Core A will also coordinate and schedule all meetings related to the function of the Program, including monthly meetings of all Project and Core leaders, and members of their respective laboratories, as well as annual meetings of the Internal and External Advisory Boards. Core A will also coordinate efforts with Dr. Armstrong, the sole off-site investigator, to travel to meetings or teleconference. Dr. Ebert is the PI and Director of this Core, and will serve as the overall scientific director and chief administrator. Dr. Griffin is the Co-Pl and will assist in these operations, particularly with regard to clinical programs, core facilities, and samples at the DFCI. He will assist Dr. Ebert in monitoring protocol performance and will assist in protocol development. Chanel Logan is a highly skilled administrator with experience in management of fiscal and administrative matters for large program project grants. She will serve as Administrative Facilitator, manage budgets between participating institutions, prepare reports including non-competing renewals, interface with the financial officers of each participating institution in the Program, and serve as an interface between these groups and the NIH. In addition, the Administrative Core will assure compliance and appropriate regulations regarding experimentation with human subjects, (including gender and minority participation) and vertebrate animals.
The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the Pl, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities.
|Wan, Liling; Wen, Hong; Li, Yuanyuan et al. (2017) ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543:265-269|
|Weisberg, Ellen L; Puissant, Alexandre; Stone, Richard et al. (2017) Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8:52026-52044|
|Pallis, Monica; Burrows, Francis; Ryan, Jeremy et al. (2017) Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget 8:16220-16232|
|Tamura, Akihiro; Hirai, Hideyo; Yokota, Asumi et al. (2017) C/EBP? is required for survival of Ly6C- monocytes. Blood 130:1809-1818|
|Toska, Eneda; Osmanbeyoglu, Hatice U; Castel, Pau et al. (2017) PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355:1324-1330|
|Shortt, Jake; Ott, Christopher J; Johnstone, Ricky W et al. (2017) A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer 17:160-183|
|Gonzalez, David; Luyten, Annouck; Bartholdy, Boris et al. (2017) ZNF143 is an important regulator of the myeloid transcription factor C/EBP?. J Biol Chem :|
|Tothova, Zuzana; Krill-Burger, John M; Popova, Katerina D et al. (2017) Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell 21:547-555.e8|
|Valerio, Daria G; Xu, Haiming; Chen, Chun-Wei et al. (2017) Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res 77:1753-1762|
|Li, Hubo; Mar, Brenton G; Zhang, Huadi et al. (2017) The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129:497-508|
Showing the most recent 10 out of 303 publications